DailyIQ
|
Sector:Basic MaterialsAll sectors
Last updated 7 minutes ago

CTVA·Corteva, Inc.

$.
+. (+.%)
After Hours
High
$85.97
Open
$83.99
Market Cap
57.48B
52W High
$87.69
Low
$83.23
P. Close
$85.70
P/E
49.47
52W Low
$60.53
Fwd P/E
20.78
DailyIQ Est.
$92.02
Technical Score (1D)
91
BUY
News Sentiment
50
MIXED
The New York Attorney General’s lawsuit accusing Corteva of contributing to toxic pollution has entered the spotlight, raising the prospect of regulatory fines and heightened ESG scrutiny. This legal pressure could force the company to allocate resources to compliance and risk mitigation, potentially tightening margins in the short term. Traders should keep an eye on court filings and any settlement talks, as a favorable outcome could ease ESG concerns while a punitive ruling could weigh on investor sentiment. Meanwhile, Corteva’s Q2 earnings are slated for release later this month, with analysts forecasting a single‑digit profit decline driven by commodity price volatility and rising input costs. The expected margin compression in the crop protection segment signals a cautious outlook, and the actual earnings report will be a key barometer for the company’s resilience to cost pressures. Investors should watch the earnings release for guidance on future margins and any updates on the company’s product pipeline, which could offset the cost headwinds. The upcoming spin‑off of Vylor and the independent crop protection entity in Q4 2026 adds further valuation uncertainty, as the separation could alter the capital structure and earnings attribution. Monitoring the separation timeline and board decisions will help gauge how the split might affect short‑term earnings and shareholder value. The partnership with Arevo to launch Arginex Soy introduces a sustainability‑focused seed treatment that could enhance Corteva’s competitive position in the soybean market, especially in Europe. Watch for farmer adoption rates and regulatory approvals of Arginex Soy, as successful uptake could improve revenue streams and offset the anticipated earnings dip.
Earnings Summary
CTVA operates as a global agricultural inputs company that supplies seed genetics and crop protection products to farmers worldwide, positioning it within the basic materials sector. Over the past six quarters, Corteva has delivered mixed earnings performance: EPS exceeded estimates in five of the six periods, with a notable miss in Q4 2025 when earnings fell to $0.22 versus an estimate of $1.17; revenue, however, has been volatile, rising from $3.978 billion in Q4 2024 to a peak of $6.456 billion in Q2 2025 before falling to $3.91 billion in Q4 2025 and rebounding to $4.905 billion in Q1 2026. Historically, the company has shown strong EPS growth in the first three quarters of 2025, but the sharp revenue decline in Q4 2025 highlights sensitivity to market conditions and product mix shifts. Recent corporate actions include the impending spin‑off of Vylor into a standalone crop‑protection entity, which introduces valuation uncertainty and could reshape investor expectations; Morningstar’s forthcoming analyst report may further influence market perception; and leadership appointments for the new entity signal a strategic focus on differentiated innovation. Investors should watch for the formal spin‑off announcement, guidance on the new crop‑protection company’s growth prospects, and any regulatory approvals that could delay the transition, as these factors will materially affect earnings forecasts and valuation multiples in the next trading cycle. Additionally, the company’s recent investment in advanced seed traits and the launch of new herbicide formulations could provide a tailwind for future revenue streams, but the impact will become clearer after the next earnings release.

EPS

EstBeatMiss
$-0.87$0.00$0.88$1.75$2.62Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.22 - -
Q1'26$1.18$1.50+27.1%
Q4'25$1.17$0.22-81.3%
Q3'25$-0.47$-0.23+50.6%
Q2'25$1.88$2.20+17.1%
Q1'25$0.88$1.13+28.2%

Revenue

EstBeatMiss
$3.5B$4.4B$5.3B$6.2B$7.1BQ1'25Q2'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.7B - -
Q1'26$4.6B$4.9B+5.8%
Q4'25$4.6B$3.9B-15.8%
Q3'25 - - -
Q2'25 - $6.5B -
Q1'25 - $4.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CTVA Stock Snapshot

CTVA is currently trading at $85.29, giving Corteva, Inc. a market cap of 57.48B and a P/E ratio of 49.5. Today's range spans $83.23–$85.97, with shares opening at $83.99 and moving down $0.41 (0.5%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 50/100.

Over the past year CTVA has traded between $60.53 and $87.69 - the current price is +40.9% off the 52-week low and -2.7% from the high. 32 analysts cover the stock with a Buy consensus and a mean 12-month target of $90.15 (range $77.00–$100.00), implying upside of +5.7%.

The bullish case for CTVA is built on complementary signals: 91/100 technical score, BUY designation, and neutral sentiment at 50/100. At $85.29 (near 52-week highs within $60.53–$87.69), the stock is at a capitalization - 57.48B - where active managers can build meaningful positions without moving the market. (P/E: 49.5) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Basic Materials.

What makes CTVA's BUY setup (91/100) particularly actionable at 57.48B in Basic Materials capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $85.29 (near 52-week highs in $60.53–$87.69), with sentiment running neutral at 50/100, the setup rewards conviction-sized positioning more than it does speculative small bets.